A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

In the first 22 months of a Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, few patients needed a temporary interruption due to left ventricular ejection fraction (LVEF) below ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

gmail.com Left ventricular ejection fraction (LVEF) has been a key variable for the diagnosis and management of heart failure over the last three decades. The British Society of Echocardiography ...

New Computational Method Reveals Congestive Heart Failure Feb. 6, 2025 — A team of physicists has developed a groundbreaking method for detecting congestive heart failure with greater ease and ...